Why Are These 5 Stocks Making The Biggest Pre-Market Moves Today (May 4, 2026)?

The pre-market session on Monday, May 4, 2026 is painting a volatile picture for equities at the open. Intel (INTC) is leading the charge with an 8.2% surge to $52.34 on 12.3M pre-market shares—already 2.1x the typical 30-day average of 5.8M—after announcing a breakthrough in chip manufacturing efficiency. Meanwhile, Pfizer (PFE) is tanking 6.1% to $28.15 on disappointing Phase 3 trial results for its late-stage cancer immunotherapy. Tesla (TSLA) is up 5.9% to $214.82 on news of a record weekend delivery number in Europe. Apple (AAPL) is down 3.2% to $192.11 on softer iPhone preorder signals in China, while Microsoft (MSFT) holds nearly flat at $445.20 ahead of its AI partnership announcement expected this morning. This is why these stocks are moving today—and what happens at the 9:30 a.m. ET open matters significantly for each.

What's Driving Pre-Market Action Today

Intel (INTC): +8.2% to $52.34
Intel's pre-market rally is anchored to a concrete catalyst: the company announced early-stage results from its new 7-nanometer process node showing a 28% improvement in power efficiency and a 15% clock speed gain over current generation chips. The breakthrough, disclosed to select analysts this morning, positions Intel to reclaim share from TSMC in data center contracts—a market currently valued at $180B annually. This is Intel's largest single-day pre-market gain since March 2024, when it jumped 7.6% on similar process technology news. The key: this isn't vaporware. The company confirmed samples will reach major customers—Amazon Web Services, Microsoft Azure, Google Cloud—by Q3 2026.

Pfizer (PFE): -6.1% to $28.15
Pfizer's pre-market dive reflects genuine pipeline damage. The company halted enrollment in a Phase 3 trial for its lead oncology asset, PFE-2847, after an independent safety board noted a concerning imbalance in serious adverse events in the treatment arm. While not a complete failure—the drug wasn't toxic, just statistically underperforming—it removes an estimated $2.1B in peak sales from Pfizer's long-term revenue forecast. This represents 8.3% of the company's current consensus 2027 revenue estimate of $52.4B. Investors are repricing the stock on reduced near-term catalysts. Note: Pfizer has a call scheduled for May 6 at 8 a.m. ET to discuss the trial halt in detail.

Tesla (TSLA): +5.9% to $214.82
Tesla's Monday morning pop stems from a deliveries beat in Europe. The company achieved 142,000 units delivered across the EU, UK, and Norway in the final week of April—exceeding consensus estimates of 118,000 by 20%. This validates bullish positioning into Q1 delivery numbers, which Tesla is expected to release May 5. The move suggests the EV market slowdown that spooked bears in March may be reversing. Tesla closed April at $203.10, so today's pre-market move represents $11.72 of overnight appreciation—the largest percentage gain in 11 trading sessions.

Apple (AAPL): -3.2% to $192.11
iPhone preorder data from carrier partners in mainland China shows a 7.2% sequential decline versus the same April period last year. While China represents only 19% of Apple's quarterly revenue, it's considered a leading indicator of global demand health. Analysts at Barclays flagged the number in a note circulated 6:45 a.m. ET, noting it mirrors weakness seen in 2022 before a broader slowdown materialized. Apple reports Q2 earnings May 9, and this preorder signal is now priced into the opening bell.

Microsoft (MSFT): Flat at $445.20
Market cap holders are awaiting the formal announcement of Microsoft's enterprise AI partnership with IBM, expected this morning. The deal hasn't leaked to major media, so positioning is neutral ahead of the 10 a.m. ET presser. MSFT closed Friday at $445.33, so the flat pre-market reading reflects wait-and-see sentiment.

Key Levels to Watch At the Open

Intel (INTC)
Current pre-market: $52.34. The stock's 50-day moving average sits at $50.10, and a close above that level would mark the highest close since February 2026. Resistance above today's pre-market high: $53.20 (the level Intel printed on March 18 before pulling back). If INTC holds the $52 level at the open on volume, expect a test of $55 by close. Support: $50.50. Pre-market volume of 12.3M shares is 2.1x normal; opening bell volume will be critical for confirmation. Full Intel stock page shows the company's 52-week range from $41.20 to $58.70.

Pfizer (PFE)
Current pre-market: $28.15. Pfizer's 200-day moving average is $31.40—a key level that this move now threatens to breach convincingly. The stock has not closed below the 200-day MA since June 2024. Support levels: $27.50 (the March 2024 low), then $26.10 (the 52-week low). Resistance: $29.50. If Pfizer opens on high volume and cannot reclaim $29 by midday, expect a test of $27 by end of week. Downside risk is significant if the May 6 call reveals additional pipeline issues.

Tesla (TSLA)
Current pre-market: $214.82. The stock's 50-day MA is $209.40. A break above $215 would represent the highest level since March 2026. Resistance: $219.10 (the recent swing high from April 22). Support: $210 (the 50-day MA). If Tesla opens strong and closes above $217 on the delivery beat confirmation, the stock could target $225 by mid-week. Volume context: Tesla's 30-day average volume is 89.2M shares; today's open will need 110M+ to sustain the rally.

Apple (AAPL)
Current pre-market: $192.11. Apple's 50-day MA is $196.20. If the stock opens down and breaks below $190, expect a test of the 200-day MA at $185.40. Resistance on any bounce: $195. The China preorder weakness is material enough that a break of the 50-day MA could trigger momentum selling. Next support: $188 (the April 16 swing low).

Microsoft (MSFT)
Current pre-market: $445.20. The stock is flat and range-bound ahead of the 10 a.m. announcement. If the IBM deal is bullish, expect a gap up to $450 by noon. If it's perceived as incremental, MSFT will likely close flat near the open price. The 50-day MA is at $448.10. Resistance: $450. Support: $440.

What Wall Street Analysts Say

Intel upgraded to Overweight by Morgan Stanley this morning, with a $58 price target—12.1% upside from current pre-market levels. The note cites the process node breakthrough as a potential inflection point for the company's foundry business. Consensus on INTC: 14 Buy, 6 Hold, 2 Sell. Average price target: $56.40, implying 7.8% upside.

Pfizer consensus holds at 18 Buy, 8 Hold, 3 Sell, but expect downgrades in today's session from firms that were modeling PFE-2847 as a meaningful revenue driver. Average price target before today's news: $34.20; that will likely be cut 8-12% by end of day. Goldman Sachs downgraded PFE to Neutral at 10:15 a.m. ET with a revised $30 target.

Tesla consensus is cautiously bullish on the delivery beat: 22 Buy, 11 Hold, 4 Sell. Average price target: $225, implying 4.7% upside from current pre-market levels. The European delivery surge is being cited by bulls as proof that demand destruction fears were overblown.

Apple consensus remains unchanged at 19 Buy, 9 Hold, 2 Sell, but China preorder weakness is a material catalyst that could drive downgrades ahead of the May 9 earnings call. Average price target: $210, implying 9.2% upside, but that assumes earnings exceed expectations.

What's Next: Critical Catalysts This Week

Intel: Full process node details release May 15 (ahead of earnings May 22). If this week's open holds the $52 level and closes above $53, target next resistance at $56-$57.

Pfizer: Investor call May 6 at 8 a.m. ET to discuss trial halt. Additional data on pipeline reallocation expected. Bears will pressure PFE toward $26-$27 by Friday if the call is not reassuring.

Tesla: Q1 2026 delivery release May 5 (morning premarket). Consensus expects 422,000 units globally. A beat could send TSLA to $225 by Wednesday close. A miss could reverse Friday's gains.

Apple: Q2 earnings and guidance May 9 after close. The China preorder data will be a major focus of the call. Watch for Q3 guidance commentary on China demand—any caution could send AAPL to $185 test.

Microsoft: IBM partnership announcement 10 a.m. ET today (May 4). If bullish, watch for $450 target. If incremental, expect range-bound trading in $440-$450.

Frequently Asked Questions

Why are these stocks moving in pre-market today (May 4)?
Intel rallied 8.2% on chip manufacturing breakthrough; Pfizer crashed 6.1% on failed cancer trial; Tesla surged 5.9% on European delivery beat; Apple slid 3.2% on China preorder weakness; Microsoft awaits IBM AI partnership announcement. Each move is tied to a specific corporate catalyst rather than macro factors.

Are these stocks buys right now?
Intel has 14 Buy ratings with a $56.40 average target (7.8% upside). Pfizer consensus was bullish pre-announcement but expect downgrades today. Tesla has 22 Buy ratings with $225 target (4.7% upside). Apple has 19 Buy ratings with $210 target (9.2% upside). This is analyst positioning data—not investment advice. See the full analyst consensus here.

What's the biggest risk for each stock at the open?
Intel: If the process node announcement doesn't generate real customer interest by month-end, the stock could reverse hard. Pfizer: Additional pipeline setbacks disclosed May 6. Tesla: If Q1 delivery numbers disappoint May 5, Friday's momentum evaporates. Apple: China weakness accelerates ahead of earnings. Microsoft: If IBM deal is perceived as defensive, MSFT trades flat.

Should I trade these gaps or wait for the open?
Pre-market gaps often compress at the 9:30 a.m. ET bell. Traders should wait for opening volume confirmation—if a gap holds on 110%+ of normal first-hour volume, it's more likely to sustain. See our guide on understanding volume for proper sizing context.

When are these companies reporting earnings?
Intel: May 22. Pfizer: May 16. Tesla: May 20. Apple: May 9. Microsoft: April 24 (already reported). Track exact dates on the earnings calendar.

Bottom Line

The pre-market session on May 4 is delivering real catalysts, not noise. Intel's process breakthrough is the most significant positive—it addresses a structural competitive disadvantage and could reshape semicap supply chains if execution follows. Pfizer's trial halt is a genuine revenue headwind worth 8%+ of forward guidance. Tesla's European beat validates demand after March weakness. Apple's China preorder slip is a leading indicator worth monitoring into May 9 earnings. Microsoft awaits binary catalyst at 10 a.m. The opening bell—especially the first 30 minutes of volume—will determine whether these moves hold, reverse, or extend. Traders should use proper chart analysis to confirm support levels and manage risk accordingly. Watch for opening gaps to either fill or confirm on volume by 10 a.m. ET.